JNK/c-Jun

JNK-1-IN-5 is a selective JNK1 inhibitor exhibiting sub-nanomolar activity. This compound effectively suppresses TGF-β-induced epithelial-mesenchymal transition, making it a valuable tool in research focused on pulmonary fibrosis. JNK-1-IN-5 provides a promising avenue for investigating the role of JNK1 in fibrogenic processes and related therapeutic interventions.

JD123 is a selective inhibitor of JNK1, demonstrating ATP-competitive inhibition of p38-γ MAPK. It effectively reduces the activity of JNK1 and the expression of cJun (1-135), while exhibiting no inhibitory effects on ERK1, ERK2, or the other p38 MAPK isoforms (α, β, and δ). JD123 is primarily utilized in research applications focused on cell signaling pathways, apoptosis, and inflammatory responses.

JNK-1-IN-1 is a potent inhibitor of c-Jun N-terminal kinase 1 (JNK-1), demonstrating additional inhibitory effects on MKK7 with an IC50 of 7.8 μM. This compound selectively targets the JNK signaling pathway, which is crucial in regulating various cellular processes such as apoptosis, inflammation, and differentiation. JNK-1-IN-1 is valuable for research applications in cancer biology, neurodegenerative diseases, and inflammatory disorders, providing insights into the modulation of JNK-related signaling pathways.

JNK-IN-22 is a selective inhibitor of JNK-1, a key regulator in the stress-activated protein kinase signaling pathway. This compound demonstrates potent inhibition of JNK-1 activity, which is implicated in various cellular processes, including apoptosis, differentiation, and inflammation. JNK-IN-22 is utilized in research to explore its role in neurodegenerative diseases, cancer, and metabolic disorders, making it a valuable tool for understanding JNK-mediated signaling pathways.

JNK-IN-25 is a highly selective inhibitor of JNK1, JNK2, and JNK3, exhibiting IC50 values of 1.54 nM, 1.99 nM, and 0.75 nM, respectively. This compound acts by covalently binding to the conserved cysteine residue in the JNK isoforms, thereby obstructing the phosphorylation of c-Jun. JNK-IN-25 is valuable for investigating pathways involved in cancer, as well as in inflammatory and neurodegenerative diseases.

CC-401 dihydrochloride is a potent inhibitor of c-Jun N-terminal kinases (JNK) with an inhibition constant (Ki) ranging from 25 to 50 nM. This compound effectively modulates JNK signaling pathways, making it valuable in studies related to cellular stress responses, apoptosis, and inflammatory processes. CC-401 dihydrochloride is applicable in various research areas, including cancer biology and neurodegenerative disease investigations.

JNK-IN-21 is a selective inhibitor of JNK-1, a member of the c-Jun N-terminal kinase family, which plays a crucial role in various cellular processes such as apoptosis and inflammation. By blocking JNK-1 activity, JNK-IN-21 demonstrates potential for modulating signaling pathways associated with stress responses and cellular differentiation. This compound is utilized in biological research to investigate JNK-related signaling mechanisms and their implications in disease models.

JNK2-IN-1 is a selective inhibitor of JNK2, displaying a dissociation constant (Kd) of 79.2 μM. This compound exhibits anti-inflammatory properties by reducing the secretion of pro-inflammatory cytokines TNF-α and IL-6 through the inhibition of the NF-κB/MAPK signaling pathway. JNK2-IN-1 has demonstrated therapeutic potential in alleviating symptoms associated with LPS-induced acute lung injury (ALI) and sepsis, making it valuable for research in inflammation and related diseases.

JNK-IN-23 is a potent inhibitor of c-Jun N-terminal kinases (JNK), demonstrating significant antiproliferative activity against MDA-MB-231 cells with a GIC50 of 30 nM. It effectively impedes metastatic growth in triple-negative breast cancer (TNBC) models in vivo, significantly reducing lung metastasis rates. JNK-IN-23 functions through the dual targeting of glutaminase-1 (GLS) and pyruvate dehydrogenase complex (PDHC), making it a valuable tool for research into cancer metabolism and metastasis.

TAT-JIP is an effective inhibitor of the phosphorylation of endogenous c-jun, particularly following activation by PHA-PMA. This compound is useful for studying the role of c-jun in various signaling pathways and cellular processes. Its application in research may extend to investigating the regulatory mechanisms involved in cell proliferation, differentiation, and response to stress.

JNK3 Inhibitor-7 is a selective inhibitor of the c-Jun N-terminal kinase 3 (JNK3) pathway, exhibiting potent activity with IC50 values of 53 nM for JNK3, while demonstrating lesser inhibition against JNK2 and JNK1 at 973 nM and 1039 nM, respectively. This compound effectively crosses the blood-brain barrier and exhibits significant neuroprotective properties. JNK3 Inhibitor-7 holds potential for research applications related to neurodegenerative disorders, particularly Alzheimer's disease.

JNK-IN-24 is a selective inhibitor of c-Jun N-terminal kinase (JNK), demonstrating significant anti-metastatic properties in cancer research. By downregulating JNK and matrix metalloproteinase 1 (MMP1) expression in Scrib knockdown-induced cancer models, JNK-IN-24 facilitates recovery from tumorous phenotypes. This compound is suitable for investigations into a range of epithelial cell-derived cancers, contributing to the understanding of JNK's role in tumor progression and metastasis.

JNK-IN-19 is a selective inhibitor of c-Jun N-terminal kinase (JNK), an important regulator in cellular stress responses. This compound demonstrates significant biological activity by modulating pathways associated with apoptosis, inflammation, and cell survival. JNK-IN-19 shows potential utility in research focused on surgical interventions, neuroprotection, and conditions characterized by oxidative stress. It provides a valuable tool for investigating the role of JNK in various physiological and pathological processes.

HE4-1 leech peptide is a selective inhibitor of p38 MAPK and c-Jun N-terminal kinase (JNK). It effectively suppresses macrophage migration while maintaining normal macrophage immunological functions, such as phagocytosis, lysozyme activity, and the expression of various inflammatory factors. This peptide is primarily utilized in research focused on atherosclerosis and inflammation-related studies.

JNK3 Inhibitor-8 is a selective, orally bioavailable inhibitor targeting the c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 21 nM. It demonstrates pronounced neuroprotective effects and effectively crosses the blood-brain barrier. This compound is relevant for research applications related to neurodegenerative disorders, particularly Alzheimer’s disease.

JNK3 Inhibitor-3 is a selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) that effectively permeates the blood-brain barrier and exhibits oral bioavailability. With IC50 values of 147.8 nM, 44.0 nM, and 4.1 nM for JNK1, JNK2, and JNK3 respectively, JNK3 Inhibitor-3 demonstrates significant inhibitory effects across these kinase targets. This compound has been shown to enhance memory performance in mouse models of dementia, making it a valuable tool for research in Alzheimer’s disease and related neurodegenerative disorders.

JNK-1-IN-4 is a selective inhibitor of the c-Jun N-terminal kinase (JNK) family, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7 nM, 19.0 nM, and 9.0 nM, respectively. This compound effectively inhibits the phosphorylation of c-Jun and decreases the expression of TGF-β1-induced epithelial-to-mesenchymal transition (EMT) marker proteins, including fibronectin and α-SMA. JNK-1-IN-4 demonstrates favorable pharmacokinetic properties, evidenced by a bioavailability of 69%, and has shown anti-fibrotic effects in bleomycin-induced models of idiopathic pulmonary fibrosis.

TOPK-p38/JNK-IN-1 is an orally active inhibitor targeting the TOPK-p38/JNK signaling pathway, exhibiting an IC50 value of 2.14 µM for nitric oxide production. This compound demonstrates significant anti-inflammatory activity by inhibiting the phosphorylation of downstream proteins while preventing degradation of TOPK. Research applications include studies on inflammatory processes and cellular signaling mechanisms in various disease models.

ZG-10 is a selective inhibitor of JNK (c-Jun N-terminal kinase), demonstrating IC50 values of 809 nM for JNK1, 1140 nM for JNK2, and 709 nM for JNK3. This compound exhibits potential therapeutic benefits in mitigating SARS-CoV-2 infection. Its biological activity positions it as a valuable tool for research into cellular signaling pathways and antiviral strategies.

SR-3737 is a potent inhibitor of JNK3 and p38 mitogen-activated protein kinases, with IC50 values of 12 nM and 3 nM, respectively. This compound exhibits significant biological activity by modulating pathways involved in stress responses and inflammation. SR-3737 is useful in research applications focusing on neuronal signaling, cytokine production, and the molecular mechanisms underlying various neurodegenerative diseases.

JNK3 Inhibitor-2 is a selective inhibitor targeting c-Jun N-terminal kinase 3 (JNK3), demonstrating an IC50 of 0.25 µM for JNK3, with minimal activity against JNK1 and JNK2 (>100 µM). This compound exhibits additional inhibitory effects on DDR1 and EGFR variants (T790M, L858R). JNK3 Inhibitor-2 is valuable for research applications focusing on cellular stress response and cancer signaling pathways, particularly in studies investigating JNK3’s role in neurodegeneration and oncogenesis.

JNK-IN-20 is a selective JNK inhibitor targeting the c-Jun N-terminal kinase pathway. This compound demonstrates significant anti-inflammatory properties and exhibits potential in cancer research by modulating cell signaling pathways involved in tumor progression. JNK-IN-20 is suitable for studies focusing on inflammatory diseases and tumorigenesis.

JD118 is a selective JNK inhibitor that predominantly targets JNK1, effectively modulating its activity and downstream signaling pathways. This compound has been shown to inhibit the expression of cJun (1–135), making it a valuable tool for research in cellular stress responses and apoptosis. JD118 is suitable for studies investigating the role of JNK signaling in various disease models, including cancer and neurodegeneration.

AS601245 TFA is a selective, ATP-competitive inhibitor of c-Jun NH2-terminal protein kinases (JNK), demonstrating IC50 values of 150 nM for hJNK1, 220 nM for hJNK2, and 70 nM for hJNK3. This compound exhibits significant selectivity, being 10- to 20-fold more selective for JNK over kinases such as c-src, CDK2, and c-Raf, and shows more than 50- to 100-fold selectivity against various Ser/Thr and Tyr-protein kinases. AS601245 TFA is suitable for applications involving neuroprotection and the study of cellular stress response pathways in research settings.